- LDS
- /Medical Tests
- /EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer
Diseases (7)Access to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
OverviewAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
Clinical UtilityAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
InterpretationAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
Reference RangesAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
MethodologyAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
Turnaround TimeAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
CPTAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
LOINCAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
ICD10Access to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
Additional ICD10Access to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.
ReferencesAccess to EdenDx Methylation Assay (CDO1 and CELF4) for Early Detection of Endometrial Cancer is restricted.